Akeso announced on December 6 that the company's second potential global FIC dual antibody product Evosi (PD-1/VEGF bispecific antibody) license out, Akeso will grant Summit Therapeutics exclusive license rights to develop and commercialize the product in the United States, Canada, Europe and Japan, and retain the development and commercialization rights of Evosil except in the above regions, including China
.
At the same time, the company has co-branded rights
to the product in the agreement license area of SUMMIT.
According to the agreement, the company will obtain a transaction amount of up to $5 billion through overseas authorization, including a down payment of up to $500 million
.
In addition, in terms of share, Akeso will receive a low double-digit share
of net sales.
Dr.
Yu Xia, Chairman and CEO of Akeso, will serve as a member of the Summit Board of Directors
.
It is worth mentioning that the transaction has set a new record of $2.
9 billion granted to Novartis by BeiGene's TIGIT, and the down payment of up to $500 million also shows that Summit is optimistic
about Iwosi's products.
So, what exactly is Ewosi? Data show that Evoxi can block PD-1 and VEGF pathways at the same time, and can exert immune effects and anti-angiogenic effects
at the same time with "one drug and two targets".
This innovative antibody structure design reduces drug treatment-related side effects and safety concerns
.
At present, no PD-1-based bispecific antibody has been approved by the United States (FDA) or the European Medicines Agency (EMA), so Ewosi is a leading PD-1/VEGF bispecific antibody
in the global clinical development progress.
The product has been recognized as three breakthrough therapies by the NMPA, including: AK112 combined with chemotherapy for the treatment of locally advanced or metastatic non-squamous non-small cell lung cancer (NSCLC) with EGFR-resistant EGFR mutations (NSCLC), which has recently completed phase III clinical trials; AK112 is the first-line treatment of PD-L1-positive locally advanced or metastatic NSCLC, which is currently undergoing phase III clinical trials; AK112 in combination with docetaxel for locally advanced or metastatic NSCLC
that has failed previous PD-(L)1 inhibitors and platinum-containing chemotherapy.
In recent years, with the improvement of the strength of domestic innovative drug enterprises, more and more domestic new drugs have been recognized by overseas pharmaceutical companies, and domestic innovative drugs have accelerated their overseas expansion with the help of license out
.
In addition to Ewosi, since 2022, there have been many cases of domestic innovative drugs going overseas through license out, many of which have a transaction value of more than 1 billion US dollars
.
For example, on July 28, CSPC announced that its subsidiary, CSPC Jushi Biologics, has reached an agreement with U.
S.
biopharmaceutical company Elevation Oncology, which has obtained an exclusive license agreement for the development and commercialization of an ADC drug SYSA1801 outside of Greater China (including Chinese mainland, Hong Kong, Macau and Taiwan), with a transaction value of nearly US$1.
2 billion, including a US$27 million down payment, Potential development and regulatory milestone payments of up to $148 million and potential sales milestone payments
of up to $1.
02 billion.
In May, Kelun Pharmaceutical announced that the company has an exclusive license for a fee to develop, manufacture and commercialize SKB-264
, an ADC drug targeting TROP2, outside of China (China includes Chinese mainland, Hong Kong, Macau and Taiwan).
The transaction includes an upfront payment of $47 million, milestone payments of up to $1.
363 billion, and a commission on net sales after launch
.
Two months later, Kelun Pharmaceutical announced again that the company will exclusively license Merck to develop, manufacture and commercialize an ADC drug for the treatment of solid tumors (Project B) worldwide, and the two parties will also cooperate
in the early clinical development of the ADC drug.
According to the agreement, Merck will pay Collun an upfront payment of $35 million, various milestone payments of up to $901 million and corresponding net sales commissions
, based on the content of the agreement and the commercial development stage.
Disclaimer: Under no circumstances does the information or opinions expressed herein constitute investment advice
to anyone.
={"common":{"bdSnsKey":{},"bdText":"","bdMini":"1","bdMiniList":false,"bdPic":"","bdStyle":"0","bdSize":"32"},"share":{},"image":{"viewList":[" weixin","sqq","qzone","tsina","tqq","tsohu","tieba","renren","youdao","fx","ty","fbook","twi","copy","print"],"viewText":"share:","viewSize":"24"},"selectShare":{" bdContainerClass":null,"bdSelectMiniList":["weixin","sqq","qzone","tsina","tqq","tsohu","tieba","renren","youdao","fx","ty","fbook","twi","copy","print"]}}; with(document)0[(getElementsByTagName('head')[0]|| body).
appendChild(createElement('script')).
src='http://bdimg.
share.
baidu.
com/static/api/js/share.
js?v=89860593.
js?cdnversion='+~(-new Date()/36e5)]; 
